Novartis Investigative Site

Taipei, Taiwan, ROC 11217

0 studies enrolling now · 22 studies all time

What they study most

Adenocarcinoma, Advanced NET of GI Origin, Advanced NET of Lung Origin, Advanced Neuroendocrine Tumors of Pancreatic Origin, Advanced Solid and Hematological TP53wt Tumors, Advanced/ Metastatic Renal Cell Cancer, Atherosclerosis, Breast Cancer, Carcinoma, Gastrointestinal Stromal Tumor (GIST), Heart Failure With Reduced Ejection Fraction, Hepatitis C

Studies at this site

• Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. — Stopped early
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) — Completed
• Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt — Completed
• A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer — Completed
• Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors — Completed
• Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer — Completed
• Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer — Completed
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer — Completed
• Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma — Completed
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma — Completed
• A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer — Completed
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. — Completed
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• A Study of Nilotinib Versus Imatinib in GIST Patients — Completed
• Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension — Completed
• Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer — Completed
• Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension — Completed
• Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors — Completed
• 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension — Completed